Drug intelligence / Profile preview

VS-S103

Development stage: Preclinical
Lead developer: Fosun Pharma
Modality: Small Molecules

Overview

VS-S103 is a preclinical-stage small molecule triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucagon receptor (GCGR), and glucose-dependent insulinotropic polypeptide receptor (GIPR). Developed by Fosun Pharma USA, it is being investigated for the treatment of metabolic disorders, including Type 2 Diabetes Mellitus (T2DM), obesity, and non-alcoholic steatohepatitis (NASH). As a small molecule agonist, it aims to provide a more convenient oral alternative to the injectable peptide-based multi-receptor agonists currently dominating the metabolic disease landscape.

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on VS-S103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-S103.

Explore the full profile